Last updated on February 2018

Study of Mirvetuximab Soravtansine in Comb. With Bevacizumab Carboplatin PLD Pembrolizumab or Bevacizumab + Carboplatin in Adults With FRa + Adv. EOC Primary Peritoneal or Fallopian Tube Cancer


Brief description of study

This is a phase 1b study to assess the safety, tolerability, and preliminary anti-tumor activity of IMGN853 when administered with chemotherapy. Patients will be assigned to one of four regimens: IMGN853 administered with bevacizumab, IMGN853 administered with carboplatin, IMGN853 administered with pegylated liposomal doxorubicin, IMGN853 administered with pembrolizumab, or IMGN853 administered with bevacizumab+carboplatin

Detailed Study Description

The dose escalation part of the study will assess safety and tolerability and determine the maximum tolerated dose (MTD) for each regimen. The dose expansion of the MTD will assess safety, tolerability and preliminary anti-tumor activity.

Clinical Study Identifier: NCT02606305

Contact Investigators or Research Sites near you

Start Over

ImmunoGen Clinical Operations

Massachusetts General Hospital
Boston, MA United States
  Connect »

ImmunoGen Clinical Operations

Dana-Farber Cancer Institute
Boston, MA United States
  Connect »

ImmunoGen Clinical Operations

The Ohio State University
Hilliard, OH United States
  Connect »

ImmunoGen Clinical Operations

Peggy and Charles Stephenson Oklahoma Cancer Center
Oklahoma City, OK United States
  Connect »

ImmunoGen Clinical Operations

Fox Chase Cancer Center
Philadelphia, PA United States
  Connect »

ImmunoGen Clinical Operations

Universitaire Ziekenhuizen (UZ) Leuven - Gasthuisberg - Leuvens Kankerinstituut
Leuven, Belgium
  Connect »

ImmunoGen Clinical Operations

McGill University
Montreal, Canada
  Connect »